In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Sergio Ortega Del CampoÁrea de Genética, Facultad de Ciencias, Campus de Teatinos, Universidad de Málaga, Málaga, Spain.ORCID 0000-0002-3975-6951 Gregorio Joaquín Fernández BallesterInstituto de Investigación en Biotecnología y Salud (IDiBE), Universidad Miguel Hernández, Elche, Spain.ORCID 0000-0002-5412-8611 Clara Blanes MiraDepartment of Public Health, History of Science and Gynecology, Universidad Miguel Hernández, Sant Joan d'Alacant, Spain.ORCID 0000-0002-9625-6275 Víctor Guirado OsorioCentro de Supercomputación y Bioinnovación (SCBI), Universidad de Málaga, Málaga, Spain.
Luis Díaz MartínezCentro de Supercomputación y Bioinnovación (SCBI), Universidad de Málaga, Málaga, Spain.ORCID 0000-0002-7659-4349 Ana Isabel de ÁvilaCentro de Biología Molecular Severo Ochoa (CBM), (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid) (CSIC-UAM), Campus de Cantoblanco, Madrid, Spain.ORCID 0000-0002-9381-0963 María Eugenia SoriaCentro de Biología Molecular Severo Ochoa (CBM), (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid) (CSIC-UAM), Campus de Cantoblanco, Madrid, Spain.ORCID 0000-0002-4719-3351 Brenda Martínez-GonzálezCentro de Biología Molecular Severo Ochoa (CBM), (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid) (CSIC-UAM), Campus de Cantoblanco, Madrid, Spain.ORCID 0000-0002-4482-5181 Francisco José Villena GonzálezÁrea de Genética, Facultad de Ciencias, Campus de Teatinos, Universidad de Málaga, Málaga, Spain.ORCID 0009-0006-9119-1093 Josefa Gómez-MaldonadoServicios Centrales de Apoyo a la Investigación (SCAI), Área de Ciencias de la Vida, Genómica, Universidad de Málaga, Málaga, Spain.ORCID 0000-0003-1570-1937 María Isabel Viciana RamosHospital Universitario Virgen de la Victoria, Campus de Teatinos, Málaga, Spain.
Encarnación Clavijo FrutosHospital Universitario Virgen de la Victoria, Campus de Teatinos, Málaga, Spain.ORCID 0000-0002-0172-5164 Jesús L Santos GonzálezHospital Universitario Virgen de la Victoria, Campus de Teatinos, Málaga, Spain.
Ugo BastollaCentro de Biología Molecular Severo Ochoa (CBM), (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid) (CSIC-UAM), Campus de Cantoblanco, Madrid, Spain.ORCID 0000-0001-9342-4678 Celia PeralesCentro de Biología Molecular Severo Ochoa (CBM), (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid) (CSIC-UAM), Campus de Cantoblanco, Madrid, Spain.ORCID 0000-0003-1618-1937 Esteban DomingoCentro de Biología Molecular Severo Ochoa (CBM), (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid) (CSIC-UAM), Campus de Cantoblanco, Madrid, Spain.ORCID 0000-0002-0573-1676 Enrique VigueraÁrea de Genética, Facultad de Ciencias, Campus de Teatinos, Universidad de Málaga, Málaga, Spain.ORCID 0000-0001-5475-3807 Ana María Fernández EscamillaInstituto de Investigación en Biotecnología y Salud (IDiBE), Universidad Miguel Hernández, Elche, Spain.ORCID 0000-0002-6615-4913 Ana Grande PérezÁrea de Genética, Facultad de Ciencias, Campus de Teatinos, Universidad de Málaga, Málaga, Spain.ORCID 0000-0002-2821-062X Funding
Fundacion Bancaria UnicajaFundacion Martin Varona Financial supportFundación Ramón Areces Research fundingGeneralitat Valenciana CIBEST/2024/114Junta de Andalucía CV20-10932Ministerio de Ciencia, Innovación y Universidades PID2023-151032NB-C2Ministerio de Ciencia, Innovación y Universidades, "Severo Ochoa" Program for Centres of Excellence in Research and Development PID2023-146622OB-I00, CEX2021-001154-SMinisterio de Universidades (MU) Teaching Staff Retraining Grant (2023)SALAINDEC-CM, Comunidad de Madrid/FEDER TEC-607 2024/BIO-66Spanish Agency of Research and FEDER AEI/10.13039/501100011033/Universidad de Málaga Open access
6 · The paper itselfAbstract
The limited durability of vaccine protection and the rapid emergence of SARS-CoV-2 variants highlight the need for antiviral strategies that extend beyond vaccination and conventional small-molecule inhibitors. Here, we explored a dual approach combining structure-guided peptides predicted to interfere with the viral replication complex with lethal mutagenesis to limit SARS-CoV-2 replication. Using the crystallographic interfaces of nsp10 with nsp14 and nsp16, we designed short inhibitory peptides predicted to interact with the viral proofreading and RNA-capping machinery. In parallel, the mutagenic analog 5-fluorouracil was evaluated to determine its effect on SARS-CoV-2 in Vero E6 cells. Peptides P1 and P6 exhibited potent antiviral activity with minimal cytotoxicity, whereas 5-FU reduced specific infectivity without impairing genome replication. Combined treatment with 5-FU and peptide P1 resulted in >10
Indexed as
Antiviral AgentsFluorouracilPeptidesSARS-CoV-2Virus ReplicationAnimalsChlorocebus aethiopsCOVID-19 Drug TreatmentDrug SynergismExoribonucleasesHumansMutagenesisVero CellsViral Nonstructural ProteinsAntiviral AgentsExoribonucleasesFluorouracilNSP14 protein, SARS-CoV-2PeptidesViral Nonstructural Proteins5-fluorouracildrug combinationExoN activitylethal mutagenesisMTase activitymutant spectransp10peptide designSARS-CoV-2synergism
Identifiers
PMID42037394
PMCPMC13231887
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390